Regulation of Advanced Glycation End Product (AGE) Receptors and Apoptosis by AGEs in Osteoblast-like Cells

Overview

Journal Mol Cell Biochem

Publisher Springer

Specialty Biochemistry

Date 2007 Jul 31

PMID 17660952

Citations 30

Authors

Natalia Mercer

Hafiz Ahmed

Susana B Etcheverry

Gerardo R Vasta

Ana Maria Cortizo

Affiliations

Soon will be listed here.

Abstract

Advanced glycation end products (AGEs) have been proposed as the pathological mechanisms underlying diabetic chronic complications. They may also play a role in the pathogenesis of diabetic osteopenia, although their mechanisms of action remain unclear. We investigated the protein (immunofluorescence) and gene expression (realtime RT-PCR) of two receptors for AGEs, RAGE and galectin-3, as well as their regulation by AGEs, and the apoptotic effect on osteoblast-like cells (UMR106 and MC3T3E1) in culture. AGEs up-regulated the expression of RAGE and galectin-3 in both cells lines. These effects were accompanied by an increase in the corresponding mRNA in the non-tumoral MC3T3E1 but not in the osteosarcoma UMR106 cells. Finally, we demonstrated that a 24 h exposure to AGEs induced apoptosis in both cell lines. Thus, AGEs-receptors may play important roles in the bone alterations described in aging and diabetic patients.

Citing Articles

Activation of BK channels prevents diabetes-induced osteopenia by regulating mitochondrial Ca and SLC25A5/ANT2-PINK1-PRKN-mediated mitophagy.

Jiang L, He H, Tang Y, Li J, Reilly S, Xin H Autophagy. 2024; 20(11):2388-2404.

PMID: 38873928 PMC: 11572260. DOI: 10.1080/15548627.2024.2367184.

The analgesic effects of insulin and its disorders in streptozotocin-induced short-term diabetes.

Basatinya A, Sajedianfard J, Nazifi S, Hosseinzadeh S Physiol Rep. 2024; 12(8):e16009.

PMID: 38639646 PMC: 11027902. DOI: 10.14814/phy2.16009.

Synergistic effect of metformin and vitamin D on osteogenic differentiation of human adipose tissue-derived mesenchymal stem cells under high d-glucose conditions.

Ha N, Huynh T, Phan N, Nguyen T, Vong L, Trinh N Regen Ther. 2024; 25:147-156.

PMID: 38486821 PMC: 10937201. DOI: 10.1016/j.reth.2023.12.003.

Low Bone Turnover Associates With Lower Insulin Sensitivity in Newly Diagnosed Drug-Naïve Persons With Type 2 Diabetes.

Nasser M, Stidsen J, Hojlund K, Nielsen J, Eastell R, Frost M J Clin Endocrinol Metab. 2023; 108(7):e371-e379.

PMID: 36718513 PMC: 10271224. DOI: 10.1210/clinem/dgad043.

Receptors of Advanced Glycation End Product (RAGE) Suppression Associated With a Preserved Osteogenic Differentiation in Patients With Prediabetes.

Phimphilai M, Pothacharoen P, Chattipakorn N, Kongtawelert P Front Endocrinol (Lausanne). 2022; 13:799872.

PMID: 35237235 PMC: 8882829. DOI: 10.3389/fendo.2022.799872.

References

McCarthy A, Etcheverry S, Cortizo A . Advanced glycation endproduct-specific receptors in rat and mouse osteoblast-like cells: regulation with stages of differentiation. Acta Diabetol. 1999; 36(1-2):45-52. DOI: 10.1007/s005920050144. View

Pugliese G, Pricci F, Leto G, Amadio L, Iacobini C, Romeo G . The diabetic milieu modulates the advanced glycation end product-receptor complex in the mesangium by inducing or upregulating galectin-3 expression. Diabetes. 2000; 49(7):1249-57. DOI: 10.2337/diabetes.49.7.1249. View

Yatoh S, Mizutani M, Yokoo T, Kozawa T, Sone H, Toyoshima H . Antioxidants and an inhibitor of advanced glycation ameliorate death of retinal microvascular cells in diabetic retinopathy. Diabetes Metab Res Rev. 2005; 22(1):38-45. DOI: 10.1002/dmrr.562. View

Vashishth D, Gibson G, Khoury J, Schaffler M, Kimura J, Fyhrie D . Influence of nonenzymatic glycation on biomechanical properties of cortical bone. Bone. 2001; 28(2):195-201. DOI: 10.1016/s8756-3282(00)00434-8. View

Liu F, Patterson R, Wang J . Intracellular functions of galectins. Biochim Biophys Acta. 2002; 1572(2-3):263-73. DOI: 10.1016/s0304-4165(02)00313-6. View

McCarthy A, Etcheverry S, Bruzzone L, Cortizo A . Effects of advanced glycation end-products on the proliferation and differentiation of osteoblast-like cells. Mol Cell Biochem. 1997; 170(1-2):43-51. DOI: 10.1023/a:1006816223292. View

Alikhani Z, Alikhani M, Boyd C, Nagao K, Trackman P, Graves D . Advanced glycation end products enhance expression of pro-apoptotic genes and stimulate fibroblast apoptosis through cytoplasmic and mitochondrial pathways. J Biol Chem. 2004; 280(13):12087-95. DOI: 10.1074/jbc.M406313200. View

Cortizo A, Lettieri M, Barrio D, Mercer N, Etcheverry S, McCarthy A . Advanced glycation end-products (AGEs) induce concerted changes in the osteoblastic expression of their receptor RAGE and in the activation of extracellular signal-regulated kinases (ERK). Mol Cell Biochem. 2003; 250(1-2):1-10. DOI: 10.1023/a:1024934008982. View

Odetti P, Rossi S, Monacelli F, Poggi A, Cirnigliaro M, Federici M . Advanced glycation end products and bone loss during aging. Ann N Y Acad Sci. 2005; 1043:710-7. DOI: 10.1196/annals.1333.082. View

10.

Brownlee M . Biochemistry and molecular cell biology of diabetic complications. Nature. 2001; 414(6865):813-20. DOI: 10.1038/414813a. View

11.

Vlassara H . Recent progress in advanced glycation end products and diabetic complications. Diabetes. 1997; 46 Suppl 2:S19-25. DOI: 10.2337/diab.46.2.s19. View

12.

Molinuevo M, Barrio D, Cortizo A, Etcheverry S . Antitumoral properties of two new vanadyl(IV) complexes in osteoblasts in culture: role of apoptosis and oxidative stress. Cancer Chemother Pharmacol. 2003; 53(2):163-72. DOI: 10.1007/s00280-003-0708-7. View

13.

Chen B, Jiang D, Tang L . Advanced glycation end-products induce apoptosis involving the signaling pathways of oxidative stress in bovine retinal pericytes. Life Sci. 2006; 79(11):1040-8. DOI: 10.1016/j.lfs.2006.03.020. View

14.

Thornalley P . Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs. Cell Mol Biol (Noisy-le-grand). 1998; 44(7):1013-23. View

15.

Hein G, Weiss C, Lehmann G, Niwa T, Stein G, Franke S . Advanced glycation end product modification of bone proteins and bone remodelling: hypothesis and preliminary immunohistochemical findings. Ann Rheum Dis. 2005; 65(1):101-4. PMC: 1797982. DOI: 10.1136/ard.2004.034348. View

16.

Kume S, Kato S, Yamagishi S, Inagaki Y, Ueda S, Arima N . Advanced glycation end-products attenuate human mesenchymal stem cells and prevent cognate differentiation into adipose tissue, cartilage, and bone. J Bone Miner Res. 2005; 20(9):1647-58. DOI: 10.1359/JBMR.050514. View

17.

Schmidt A, Yan S, Yan S, STERN D . The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta. 2000; 1498(2-3):99-111. DOI: 10.1016/s0167-4889(00)00087-2. View

18.

Alikhani M, Alikhani Z, Boyd C, MacLellan C, Raptis M, Liu R . Advanced glycation end products stimulate osteoblast apoptosis via the MAP kinase and cytosolic apoptotic pathways. Bone. 2006; 40(2):345-53. PMC: 1913208. DOI: 10.1016/j.bone.2006.09.011. View

19.

Vlassara H, Li Y, Imani F, Wojciechowicz D, Yang Z, Liu F . Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex. Mol Med. 1995; 1(6):634-46. PMC: 2229987. View

20.

Forbes J, Cooper M, Thallas V, Burns W, Thomas M, Brammar G . Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes. 2002; 51(11):3274-82. DOI: 10.2337/diabetes.51.11.3274. View